MV
Morningside Venture Capital
Venture CapitalActiveMorningside Venture Capital (вАЬMorningsideвАЭ) is one of ChinaвАЩs earliest early-stage venture investors.
Xuhui, ChinaFounded 2006
197
Investments
9
Exits
$2B
AUM
4.6%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Morningside Venture Capital.
Investment Thesis & Strategy
Morningside Venture Capital invests in early-stage fintech companies, leveraging its experience as one of China's earliest venture investors. They likely seek innovative companies with high growth potential in the fintech sector.
Investment Activity
Deals per year over the last 9 years
2
20100
20110
20120
20131
20143
20152
20162
20172
2018Portfolio Companies
Selected investments from their portfolio of 197 companies
N
Nuvation Bio
Biotech · Series A, 2018
E
Epiphron
Biotech · Series A, 2018
H
Harbour BioMed
Biotech · Series B, 2017
A
Adagene
Biotech · Series B, 2017
C
CStone Pharmaceuticals
Biotech · Series B, 2016
X
XtalPi
Biotech · Series B, 2016
I
Insilico Medicine
Biotech · Series A, 2015
i
iCarbonX
Healthcare · Series A, 2015
I
Innovent Biologics
Biotech · Growth, 2015
Z
Zai Lab
Biotech · Growth, 2014
B
BeiGene
Biotech · Growth, 2010
B
Bio-Thera Solutions
Biotech · Growth, 2010
Notable Exits
CompanyTypeYearValue / Acquirer
XtalPiAcquisition2024—
Gan & Lee PharmaceuticalsIPO2021$1.2B
Harbour BioMedIPO2020$200M
CStone PharmaceuticalsIPO2019$400M
Innovent BiologicsIPO2018$3.3B
WuXi AppTecIPO2018$8.8B
Zai LabIPO2017$150M
BeiGeneIPO2016$750M
3SBioIPO2009$400M
Frequently Asked Questions
Morningside Venture Capital focuses on Series A, Series B, Series C+ stage investments.